ELITE PHARMACEUTICALS, INC /NV/— Sankey Diagram

Quarterly mode · period ending 2025-12-31 · SEC EDGAR

ComparingFY2025 (Q1+Q2+Q3+Q4) vs FY2024 (Q1+Q2+Q3+Q4)
Revenue
$140M
↑+100.2% +$70Mvs FY2024 (Q1+Q2+Q3+Q4)
Gross Profit
$72M
↑+131.5% +$41Mvs FY2024 (Q1+Q2+Q3+Q4)
Operating profit
$50M
↑+311.3% +$38Mvs FY2024 (Q1+Q2+Q3+Q4)
Net profit
$33M
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
Reconciled values per the quarterly mode pipeline. Compare against SEC EDGAR filings.
Line itemFY2025 (Q1+Q2+Q3+Q4)FY2024 (Q1+Q2+Q3+Q4)
Revenue$140M$70M
COGS$69M$39M
Gross Profit$72M$31M
R&D$6M$8M
SG&A$0$0
D&A$1M$1M
Other OpEx$14M$10M
Operating Income$50M$12M
Interest Exp.$114K$135K
Other Non-Op$3M$12M
Pretax Income$47M$0
Tax$14M$0
Net Income$33M$0

QuarterCharts · SEC EDGAR data · ELTP · Comparing FY2025 (Q1+Q2+Q3+Q4) vs FY2024 (Q1+Q2+Q3+Q4)